<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------------
Form 10-QSB
(X) Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the Quarterly Period ended September 30, 1997
( ) Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from ____________________ to _________________
Commission file number 0-21595
Enamelon, Inc.
(Exact name of registrant as specified in its charter)
Delaware 13-3669775
(State of Incorporation) (I.R.S. Employer Identification No.)
15 Kimball Avenue, Yonkers, New 10704
(Address of principal executive offices) (Zip Code)
(Registrant's telephone number, including area code) (914) 237-1308
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes X No
----- ------
APPLICABLE ONLY TO CORPORATE ISSUERS
State the number of shares outstanding of each of the issuers classes of common
equity, as of the latest practicable date: 9,927,148 shares of common stock,
$.001 par value as of November 7, 1997.
Transitional Small Business Disclosure Format (check one):
Yes No X
----- ------
<PAGE>
Part I Financial Information
Item 1. Financial Statements
Enamelon, Inc.
(A development stage company)
Balance Sheet
September 30,
1997
----------------
(unaudited)
Assets
Current:
Cash and cash equivalents ............................. $ 17,101,189
Accounts receivable ................................... 201,095
Inventory ............................................. 857,925
Prepaid expenses and other assets ..................... 203,190
------------
Total currents assets ............................... 18,363,399
Equipment, less accumulated depreciation of $139,018 .... 1,289,546
Deferred costs, less accumulated amortization of $52,879 384,827
Other assets - security deposits ........................ 15,231
------------
Total assets ............................................ $ 20,053,003
============
Liabilities and Stockholders' Equity Current liabilities:
Accounts payable ...................................... $ 1,558,530
Accrued expenses ...................................... 1,176,362
------------
Total current liabilities ........................... 2,734,892
------------
Commitments
Stockholders' equity (note 2)
Preferred stock, $0.01 par value - shares
authorized 5,000,000; none issued or outstanding .... --
Common stock, $0.001 par value - shares authorized
20,000,000; issued and outstanding 8,101,386 ........ 8,101
Additional paid-in capital .............................. 29,694,181
Accumulated deficit during the development stage ........ (12,384,171)
------------
Total stockholders' equity ............................ 17,318,111
------------
Total liabilities and stockholders' equity .............. $ 20,053,003
============
See accompanying notes to financial statements.
<PAGE>
Enamelon, Inc.
(A development stage company)
Statement of Operations
(Unaudited)
<TABLE>
<CAPTION>
Period from
Three months ended Nine months ended June 9, 1992
September 30, September 30, (Inception) to
September 30,
1997 1996 1997 1996 1997
------------- ------------ ------------- ------------- -------------
<S> <C> <C> <C> <C> <C>
Expenses:
Marketing and selling ....................... $ 1,649,801 $ 24,179 $ 4,020,813 $ 65,783 $ 4,385,395
Research and development .................... 711,343 564,853 2,052,953 1,238,839 4,682,048
Administrative and other .................... 587,912 212,410 1,685,139 582,046 3,776,139
------------- ------------ ------------- ------------- --------------
Total expenses ............................ 2,949,056 801,442 7,758,905 1,886,668 12,843,582
Other charges (income):
Interest and dividends ........................ (252,551) (25,021) (493,147) (93,500) (729,380)
Write-off of deferred offering costs .......... -- -- -- -- 269,969
------------- ------------ ------------- ------------- --------------
Net loss ...................................... $ (2,696,505) $ (776,421) $( 7,265,758) $( 1,793,168) $( 12,384,171)
============= ============ ============= ============= ==============
Net loss per common share (note 2) ............ $ (0.33) $ (0.15) $ (0.99) $ (0.33)
============= ============ ============= =============
Weighted average common shares outstanding..... 8,101,386 5,200,378 7,332,558 5,362,024
============ ============ ============ =============
</TABLE>
See accompanying notes to financial statements.
<PAGE>
Enamelon, Inc.
(A development stage company)
Statements of Stockholders' Equity
<TABLE>
<CAPTION>
Common Stock Additional Accumulated Total
-------------------------- paid-in deficit during the stockholders'
Shares Par Value capital development stage equity
--------- --------- ------------ ------------------- -------------
<S> <C> <C> <C> <C> <C>
Balance, December 31, 1996 6,900,378 $ 6,900 $ 16,409,926 $ (5,118,413) $ 11,298,413
Options and warrants exercised
(unaudited) 121,008 121 208,412 -- 208,533
Issuance of common stock at
June 30, 1997 (unaudited) 1,080,000 1,080 13,075,843 13,076,923
Net loss (unaudited) -- -- -- (7,265,758) (7,265,758)
--------- ------- ------------ -------------- -------------
Balance, September 30, 1997 8,101,386 $ 8,101 $ 29,694,181 $ (12,384,171) $ 17,318,111
========= ======= ============ ============== =============
</TABLE>
See accompanying notes to financial statements.
<PAGE>
Enamelon, Inc.
(A development stage company)
Statements of Cash Flows
(unaudited)
<TABLE>
<CAPTION>
Period from
Nine months ended June 30, 1992
September 30, (Inception) to
1997 1996 September 30, 1997
-------------- -------------- -------------------
<S> <C> <C> <C>
Cash flows from operating activities:
Net loss ...................................................... $ (7,265,758) $ (1,793,168) $ (12,384,171)
Adjustments to reconcile net loss to net cash provided by
(used in) operating activities:
Write-off of deferred offering costs ...................... -- -- 269,969
Stock issued for services ................................. -- 26,824 174,519
Depreciation and amortization ............................. 102,638 42,247 191,895
Change in operating assets and liabilities:
Accounts receivable ......................................... (201,095) -- (201,095)
Prepaid expenses and other assets ........................... (16,192) (76,853) (219,553)
Inventory ................................................... (804,742) -- (857,925)
Accrued expenses and account payable ........................ 1,701,153 168,585 2,489,170
-------------- -------------- ---------------
Net cash used in operating activities ....................... (6,483,996) (1,632,365) (10,537,191)
------------- -------------- ---------------
Cash flows from investing activities:
Purchases of equipment ........................................ (938,886) (281,637) (1,428,564)
Patents, trademarks and licenses .............................. (91,747) (107,523) (389,928)
-------------- -------------- ---------------
Net cash used in investing activities ...................... (1,030,633) (389,160) (1,818,492)
-------------- -------------- ---------------
Cash flows from financing activities:
Proceeds from sale of common stock ............................ 14,248,533 -- 29,992,850
Proceeds from sale of preferred stock ......................... -- 2,004,000 2,025,000
Offering costs ................................................ (1,022,609) (420,153) (2,560,978)
-------------- -------------- ---------------
Net cash provided by financing activities ....................... 13,225,924 1,583,847 29,456,872
-------------- -------------- ---------------
Net increase (decrease) in cash and cash equivalents ............ 5,711,295 (437,678) 17,101,189
Cash and cash equivalents, beginning of period .................. 11,389,894 1,790,666 --
-------------- -------------- ---------------
Cash and cash equivalents, end of period ........................ $ 17,101,189 $ 1,352,988 $ 17,101,189
============== ============== ===============
Supplemental disclosures of noncash financing activities:
The Company issued common stock for professional services
performed by unrelated parties .............................. $ -- $ 26,824 $ 331,854
============== ============== ===============
Accrued Offering Costs .......................................... $ 7,191 $ --
============== ==============
</TABLE>
See accompanying notes to financial statements.
<PAGE>
Enamelon, Inc.
(A development stage company)
Notes to the Financial Statements
(unaudited)
1. Statement of information furnished
The accompanying unaudited financial statements have been prepared in
accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-QSB and Item 310 of Regulation
S-B. Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial
statements. In the opinion of management, all adjustments (consisting of normal
recurring accruals) necessary for a fair presentation have been included.
Results for the interim period ended September 30, 1997 are not necessarily
indicative of results for the entire year.
For further information, refer to the financial statements and
footnotes thereto included in the Company's annual report filed on Form 10-KSB
for the year ended December 31, 1996 and the registration statement on Form
S-1, No. 333-35187, filed with the Securities and Exchange Commission on
September 8, 1997.
2. Amounts per share
Net loss per share is presented for the nine months ended September 30,
1996 on a pro forma basis to give effect to the conversion of the redeemable
preferred stock as a result of the public offering consummated in October 1996.
The calculation of net loss per share reflects the conversion of the preferred
stock as if it occurred on January 1, 1996.
The weighted average number of common shares outstanding used in
computing the pro forma net loss per common share was adjusted for the effects
of the application of Securities and Exchange Commission (SEC) Staff Accounting
Bulletin (SAB) No.83. Pursuant to SAB No. 83, common stock issued by the Company
at a price less than the initial public offering price during the twelve months
immediately preceding the initial public offering, together with common stock
purchase warrants and options issued during such period with an exercise price
less than the initial public offering price, are treated as outstanding through
June 30, 1996. Earnings (loss) per share are computed using the treasury stock
method, under which the number of shares outstanding reflects an assumed use of
the proceeds from the issuance of such shares and from the assumed exercise of
such warrants and options, to repurchase shares of the Company's common stock at
the initial public offering price.
3. Inventory is summarized as follows:
September 30,
1997
-------------
Raw materials $ 250,972
Work in process 141,560
Finished goods 465,393
---------
$ 857,925
=========
Inventories are valued at cost by the first-in, first-out method.
<PAGE>
Enamelon, Inc.
(A development stage company)
Notes to the Financial Statements
(unaudited)
(continued)
4. Private placement
In June 1997, the Company completed a private placement of 1,080,000
shares of common stock at $13.00 per share. Cash proceeds net of costs were
approximately $13.1 million. In connection with the offering the Company filed a
Registration Statement on Form S-1 with the Securities and Exchange Commission
on July 11, 1997, which became effective August 11, 1997.
5. Subsequent Event
In October 1997, the Company completed a public offering of 1,725,000
shares of common stock at $16.50 per share. Cash proceeds net of costs were
approximately $26.4 million. In connection with the offering the Company filed a
registration statement on Form S-1, No. 333-35187, with the Securities and
Exchange Commission on September 8, 1997.
<PAGE>
Item 2.
Management's Discussion and Analysis
of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction
with the Financial Statements and Notes thereto appearing in the Company's
Annual Report on Form 10-KSB, for the year ended December 31, 1996 and the
registration statement on Form S-1, No. 333-35187, filed with the Securities
and Exchange Commission on September 8, 1997.
General
Enamelon, Inc. is focused on developing and marketing over-the-counter
oral care products that stop cavities before they begin. The Company's products
are based on proprietary formulations and technologies that have been shown in
animal and in vitro studies to enhance remineralization of tooth enamel and to
prevent early stage tooth decay. Enamelon(TM) anticavity fluoride toothpaste
contains the active ingredient sodium fluoride, plus calcium and phosphate ions,
to enhance the remineralization of tooth enamel. The Company has launched its
initial product, Enamelon(TM) all-family toothpaste, into markets comprising
approximately 5% of United States households and expects to begin a national
introduction in the first quarter of 1998. The Company is also consumer testing
an adult toothpaste for sensitive teeth and expects to begin the national
introduction of that product in late 1998.
The Company began to test market Enamelon(TM) anticavity fluoride
toothpaste in several representative markets in March 1997. Test marketing and
additional clinical human studies to substantiate expected marketing claims,
including comparative advertising claims, are expected to continue throughout
1997. Assuming the successful completion of test marketing, a national roll-out
of Enamelon(TM) anticavity fluoride toothpaste is expected to occur in the first
quarter of 1998, at which time management anticipates the Company emerging from
the development stage. The Company expects to continue to incur operating losses
at least through 1999 and may require additional financing to continue its
operations thereafter.
Results of Operations
Three Months ended September 30, 1997 compared to Three Months
ended June 30, 1996.
Total expenses were approximately $2,949,000 for the three months ended
September 30, 1997, compared with total expenses of approximately $801,000 for
the same period in the prior year, an increase of $2,148,000. This increase was
primarily the result of higher marketing and selling expenses of $1,626,000,
higher research and development expenses of $146,000, and higher administrative
and other expenses of $376,000.
Marketing and selling expenses increased from $24,000 to $1,650,000
primarily as a result of the efforts to support the launch of the Company's
initial toothpaste product into test market. In addition, the Company had
expenditures relating to the consumer testing of its package design, product
appeal and product performance of the initial formulation of the Company's
toothpaste for sensitive teeth. The Company began to ship Enamelon(TM)
anticavity fluoride toothpaste into test market on March 26, 1997. For financial
reporting purposes the Company is still considered to be in the development
stage. Marketing expenses for the three months ended September 30, 1997 have
been offset by approximately $361,000 of revenues from Enamelon(TM) anticavity
fluoride toothpaste sold in test markets.
<PAGE>
Management's Discussion and Analysis
of Financial Condition and Results of Operations
(continued)
Research and development expenses increased from $565,000 to $711,000
primarily as a result of studies performed at universities and research
facilities and development activities to broaden the additional marketing claims
for consumers and dentists. The Company is continuing to expand its clinical
testing after successfully conducting in vitro and animal studies and starting
intraoral and small scale human clinical studies. The Company believes that the
results from the initial intraoral and pilot clinical programs are encouraging.
Based on the results of these studies, the Company has initiated larger,
longer-term clinicals using the more promising techniques and ideas generated in
the initial clinical testing phase.
Administrative and other expenses increased from $212,000 to $588,000
primarily attributable to increased payroll and benefits, consulting and other
administrative office expenses, which resulted from the Company's expanded
operations.
Interest and dividend income increased from $25,000 to $253,000
primarily due to the increase in cash and cash equivalents from the Company's
initial public offering in October 1996 and the private placement in June, 1997.
Nine Months ended September 30, 1997 Compared to Nine Months ended
September 30, 1996.
Total expenses were approximately $7,759,000 for the nine months ended
September 30, 1997, compared with total expenses of approximately $1,887,000 for
the same period in the prior year, an increase of $5,872,000. This increase was
primarily the result of higher marketing and selling expenses of $3,955,000,
higher research and development expenses of $814,000, and higher administrative
and other expenses of $1,103,000.
Marketing and selling expenses increased from $66,000 to $4,021,000
primarily as a result of the efforts to support the launch of the Company's
initial toothpaste product into test market. The Company began to ship
Enamelon(TM) anticavity fluoride toothpaste into test market on March 26, 1997.
For financial reporting purposes the Company is still considered to be in the
development stage. Marketing expenses for the nine months ended September 30,
1997 have been offset by approximately $693,000 of revenues from Enamelon(TM)
anticavity fluoride toothpaste sold in test markets.
Research and development expenses increased from $1,239,000 to
$2,053,000 primarily as a result of studies performed at universities and
research facilities and development activities to broaden the additional
marketing claims for consumers and dentists. The Company is continuing to expand
its clinical testing after successfully conducting in vitro and animal studies
and starting intraoral and small scale human clinical studies.
Administrative and other expenses increased from $582,000 to $1,685,000
primarily attributable to increased payroll and benefits, consulting and other
administrative office expenses, which resulted from the Company's expanded
operations.
Interest and dividend income increased from $93,000 to $493,000
primarily due to the increase in cash and cash equivalents from the Company's
initial public offering in October, 1996 and private placement in June, 1997.
Liquidity and Capital Resources
Since its inception in June 1992 through September 30, 1997 the
Company financed its
operations primarily through private placements of Series A Preferred Stock and
Common Stock and a public offering of Common
<PAGE>
Management's Discussion and Analysis
of Financial Condition and Results of Operations
(continued)
Stock totaling approximately $29.5 million, net of expenses. In June
1997, the Company completed a Private Placement of 1,080,000 shares of Common
Stock at $13.00 per share. Net cash proceeds from this offering were
approximately $13.1 million. At September 30, 1997, the Company had cash and
cash equivalents of approximately $17.1 million and working capital of $15.6
million. In October 1997, the Company completed a public offering of 1,725,000
shares of common stock at $16.50 per share. Cash proceeds net of costs were
approximately $26.4 million. The Company had no outstanding debt (other than
accounts payable and accrued expenses) or available lines of credit as of
September 30, 1997.
Since its inception and through September 30, 1997, the Company
incurred losses aggregating approximately $12.4 million and had available net
operating loss carryforwards as of December 31, 1996 of approximately $5.1
million. The net operating loss carryforwards will expire if not used by the
period from 2007 through 2011 and may be limited by United States federal tax
law as a result of future changes in ownership. The Company expects to continue
to incur operating losses at least through 1999 while it continues clinical
testing and initial toothpaste marketing efforts. In March 1997, the Company
began to test market Enamelon(TM) anticavity fluoride toothpaste in selected
United States markets. Assuming the successful completion of test marketing, the
Company intends to begin a national roll-out of this product in the first
quarter of 1998.
Since its inception and through September 30, 1997, the Company
paid $1,429,000 for the purchase of equipment and approximately $390,000 for
costs associated with obtaining patents, trademarks and license rights.
The Company's cash requirements may vary materially from those now
planned depending on numerous factors, including the status of the Company's
marketing efforts, the Company's business development activities, the
availability of alternative financing for the acquisition of manufacturing
equipment, the results of clinical trials, the regulatory process and
competition. The Company currently estimates that cash and cash equivalents on
hand, together with the net proceeds from the October 1997 offering, will be
sufficient to finance its operating losses, working capital and other
requirements for a period of approximately two years. Thereafter, or sooner if
conditions necessitate, the Company may need to raise additional funds through
public or private financing. If adequate funds are not available, then the
Company may be required to delay, reduce the scope of, or eliminate the
commercial introduction of its toothpaste products and otherwise reduce the
proposed operations.
The foregoing discussion should be read in conjunction with the
Financial Statements and Notes thereto appearing elsewhere in this report and in
the Company's Form 10-KSB for the year ended December 31, 1996, its Quarterly
Reports on Form 10-QSB for the three months ended March 31, 1997 and June 30,
1997 and the registration statement on Form S-1 filed on October 16, 1997.
Except for the historical information contained herein, the foregoing discussion
contains forward-looking statements that involve risks and uncertainties. The
Company's actual results could differ materially from those projected in the
forward-looking statements discussed herein. Factors that could cause actual
results to differ materially include, but are not limited to, the following:
acceptance of the Company's products by consumers; the Company's ability to
procure additional financing from time to time as necessary to maintain its
operations until it becomes profitable; changes in Food and Drug administration
and Federal Trade Commission regulations as they apply to the Company's
products; and challenges to patents either licensed to or held directly by the
Company. Those and other risks are described in the Company's Annual Report on
Form 10-KSB for the year ended December 31, 1996, its 1997 quarterly reports on
Form 10-QSB, and the registration statement on Form S-1, No. 333-35187 filed on
September 8, 1997.
<PAGE>
Management's Discussion and Analysis
of Financial Condition and Results of Operations
(continued)
Effect of New Accounting Pronouncement
In February 1997, the FASB issued SFAS No. 128, "Earnings Per Share."
In accordance with this statement, basic earnings per share are based on the
weighted average shares outstanding during the period and diluted earnings per
share are based on the average number of common shares and all delutive
potential common shares that were outstanding during the period. Effective
December 15, 1997, the Company will adopt this statement. The effect of the
adoption will not have a material impact on the Company's net loss per share
previously reported.
In June 1997, SFAS 130, "Reporting Comprehensive Income," and SFAS 131,
"Disclosures about Segments of an Enterprise and Related Information," were
issued. SFAS 130 addresses standards for reporting and display of comprehensive
income and its components and SFAS 131 requires disclosure of reportable
operating segments. Both statements are effective for the for the Company's 1999
fiscal year. The Company will be reviewing these pronouncements to determine
their applicability to the to the Company, if any.
<PAGE>
Part II. - Other Information
Item 2. Changes in Securities and Use of Proceeds.
(c) On June 26, 1997, the Company completed a private placement of
1,080,000 shares of Common Stock at $13.00 per share to accredited investors
for a total purchase price of $14,040,000 (the "Private offering"). Allen &
Company Incorporated and Dillion, Read & Co., Inc. acted as the placement agents
and received a sales commission of 6% of the aggregate proceeds of the Private
Offering. The Private Offering was exempt from the registration requirements of
the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Rule
506 of Regulation D promulgated under the Securities Act and Section 4(2)
thereof.
In September 1997, the Company sold 2,000 shares of Common Stock
pursuant to the exercise of 2,000 options of the Company. Said sale was exempt
from the registration requirements of the Securities Act pursuant to Section
3(b) of the Securities Act and Rule 701 promulgated thereunder.
(d) In October 1996, the Company completed its initial public offering
of 1,700,000 shares of Common Stock for net proceeds to the Company of
$11,067,000. The Company's registration statement, File No. 333-06455 with
respect to such offering, was declared effective on October 23, 1996.
From the effective date of the Securities Act registration statement to
September 30, 1997, the amount of net offering proceeds to the Company used for
various purposes was as follows:
Purchase and installation of machinery and equipment $ 1,029,000
Working capital 820,000
Sales and Marketing 4,318,000
Research and Development 2,859,000
General and Administrative 2,041,000
-----------
Total $11,067,000
===========
A reasonable estimate for the amount of net offering proceeds applied
has been provided instead of the actual amount of net offering proceeds used.
The total net offering proceeds applied represents application by the Company of
all the net offering proceeds from its initial public offering. All payments
were direct or indirect payments to persons other than directors, officers,
general partners of the Company or their associates, persons owning 10 percent
or more of any class of equity securities of the Company, and affiliates of the
Company other than amounts used to pay compensation to officers in the ordinary
course of business.
Item 5. Other Information
The Company has been advised by the Company's contract manufacturer
that one of its union contracts will expire on November 30, 1997. The contract
manufacturer expects to enter into a new contract prior to November 30, 1997. In
the event that a new contract is not signed, the contract manufacturer has
stated that a contingency plan will be put into effect, which will enable it to
continue to produce the Company's product in such quantities as may be required
by the Company. There can be no assurance however that the contract manufacturer
will be able to negotiate a new contract or that its contingency plan will be
effective. In that event, the Company will be required to seek another contract
manufacturer, which may delay its ability to manufacture and distribute the
Company's product in a timely manner.
<PAGE>
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
27.1 Financial Data Schedule
(b) No Reports on Form 8-K were filed during the quarter for which
this report is filed.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
Enamelon, Inc.
Date November 12, 1997 By /s/ Dr. Steven R. Fox
-------------------- -------------------------
Chairman of the Board of Directors
and Chief Executive Officer
(Principal Executive Office)
Date November 12, 1997 By /s/ Edwin Diaz
-------------------- -------------------------
Vice President-Finance,
Chief Financial Officer and
Treasurer
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This Schedule contains summary financial information extracted from the
Enamelon, Inc. Balance Sheet as of September 30, 1997 and the Condensed
Statement of Operations for the nine months ended September 30, 1997 and is
qualified in its entirety by reference to such financial statements.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> SEP-30-1997
<CASH> 17,101,189
<SECURITIES> 0
<RECEIVABLES> 216,259
<ALLOWANCES> 15,164
<INVENTORY> 857,925
<CURRENT-ASSETS> 18,363,398
<PP&E> 1,428,564
<DEPRECIATION> 139,018
<TOTAL-ASSETS> 20,053,003
<CURRENT-LIABILITIES> 2,734,891
<BONDS> 0
0
0
<COMMON> 8,101
<OTHER-SE> 17,310,011
<TOTAL-LIABILITY-AND-EQUITY> 20,053,003
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 7,758,905
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (493,147)
<INCOME-PRETAX> (7,265,758)
<INCOME-TAX> 0
<INCOME-CONTINUING> (7,265,758)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (7,265,758)
<EPS-PRIMARY> (0.99)
<EPS-DILUTED> (0.99)
</TABLE>
